Cognitive Impairment Associated With Schizophrenia
This is a case-based activity with a focus on cognitive impairment associated with schizophrenia (CIAS), specifically related to the pathophysiology of symptoms and the overall burden of the disease. Additionally, you’ll learn about ongoing developments in clinical research to assess the potential impact on limitations associated with the current clinical management of CIAS.
Cost: Free
View Offer chevron_rightKey Features
The France Foundation’s EXPAND™ activities allow learners to explore the core case presented in the modules and their teaching points, as well as the teaching points for each modifier developed by expert faculty.
Topics Covered
pathophysiology of symptoms associated with schizophrenia, cognitive impairment associated with schizophrenia, differentiating cognitive symptoms from positive or negative symptoms, the burden of cognitive impairment associated with schizophrenia (CIAS), ongoing developments in clinical research to help address current limitations in the management of CIAS
Learning Objectives
- Differentiate cognitive impairment from other positive or negative symptoms associated with schizophrenia
- Recognize the burden of cognitive impairment among patients with schizophrenia
- Assess how ongoing developments in clinical research may help address current limitations in the management of CIAS
Target Audience
Psychiatrists and Nurse Practitioners/Physician Associates with a focus in psychiatry
Additional credit info
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians and should claim only the credit commensurate with the extent of their participation in the activity. The France Foundation designates this activity for 1.0 ANCC contact hours. The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until July 3, 2024. PAs should only claim credit commensurate with the extent of their participation.